Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3939214 | 0.79 | TRPV4 (0.46) | L3MBTL1SMN1; SMN2ALPLGAA | |
| SCHEMBL4098349 | 0.79 | KDM4E (0.40) | SMN1; SMN2MAPK1MAPTALPLALDH1A1 | |
| SCHEMBL3938488 | 0.77 | ALPL (0.38) | MAPK1ALPLALDH1A1 | |
| SCHEMBL3939927 | 0.76 | CYP19A1 (0.44) | MAPK1ALPLALDH1A1 | |
| SCHEMBL3939973 | 0.75 | HTR6 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13371219 | 0.71 | CA12 (0.50) | L3MBTL1CA12CA1CA2CA7 | |
| SCHEMBL29022091 | 0.71 | CYP1A1 (0.68) | MAPK1MAPTALDH1A1 | |
| SCHEMBL29021978 | 0.71 | CYP1A1 (0.68) | MAPK1MAPTALDH1A1 | |
| SCHEMBL30442438 | 0.70 | CYP1A1 (0.51) | MAPK1MAPTALDH1A1 | |
| SCHEMBL29022038 | 0.69 | CYP1A1 (0.54) | MAPK1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1419143-B1 | 24-SULFUR-SUBSTITUTED ANALOGS OF 1ALPHA,25-DIHYDROXY VITAMIN D3 | UNIV JOHNS HOPKINS (US) | 2009-04-15 | — | — | EP | disclosed |
| US-7166585-B2 | 24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3 | CYTOCHROMA INC. (CA) | 2007-01-23 | — | — | US | disclosed |
| US-20040132695-A1 | 24-Sulfur-substituted analogs of 1 alpha, 25-dihydroxy vitamin D3 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-07-08 | — | — | US | disclosed |
| EP-1419143-A1 | 24-SULFUR-SUBSTITUTED ANALOGS OF 1ALPHA,25-DIHYDROXY VITAMIN D3 | JOHNS HOPKINS UNIVERSITY (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030149005-A1 | 24-sulfur-substituted analogs of 1alpha, 25-dihydroxy vitamin D3 | Opko IP Holdings II, Inc. (KY) | 2003-08-07 | — | — | US | disclosed |
| WO-2003018545-A1 | 24-SULFUR-SUBSTITUTED ANALOGS OF 1Α,25-DIHYDROXY VITAMIN D¿3? | JOHNS HOPKINS UNIVERSITY (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149005-A1 | 24-sulfur-substituted analogs of 1alpha, 25-dihydroxy vitamin D3 | CYP24A1, CYP2R1, CYP27B1 | L3MBTL1 2442/4885CA12 2873/4885CA1 2899/4885 |
| US-20040132695-A1 | 24-Sulfur-substituted analogs of 1 alpha, 25-dihydroxy vitamin D3 | CYP24A1, CYP2R1, CYP27B1 | L3MBTL1 2376/4885CA12 2669/4885CA1 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.